Biologics development:
The first ever use of base-edited T-cells via CD7 Chimeric Antigen Receptor (CAR)-T cell therapy was done on a thirteen-year-old patient suffering from relapsed T-cell acute lymphoblastic leukemia (T-ALL). This therapy helped them to achieve remission 28 days later.
The patient had a second bone marrow transplant after the therapy. And after six months the patient was doing well and getting recover at home. However, before, the patient had unsuccessful conventional treatments including chemotherapy and a bone marrow transplant and was only left with palliative care. Therefore, the new biologics development of base-edited T-cells could be a new era of cancer treatment.
Moreover, the new base editing is done, allowing more editing. This will minimize the risks of unwanted effects on chromosomes compared to the previous approaches of TALENS or CRISPR/Cas9. The research was conducted by the collaboration of University College London (UCL) and Great Ormond Street Hospital for Children (GOSH) and the data is presented at the 2022 American Society of Hematology (ASH) annual meeting.
According to the researchers, the base-edited T-cells are created by removing the existing receptors to make it universal, then removing the CD7 T-cell marker to prevent it from destruction. Followed by removing of CD52 to make the edited cells invisible to the strong drugs. Further, a CAR is added to recognize the CD7 T-cell receptor on leukemic T-cells. Therefore, the cells can now recognize and fight against T cell leukemia. These edits are basically done by changing the single nucleotide bases of DNA.
As per the eminent personalities, further research is required on advanced therapies of CAR T-cell therapy for chronic diseases. For instance, Dr Robert Chiesa, recommends further monitoring and confirming the result over the next few months. Dr Louise Jones recommends developing advanced therapies based on genes, tissues or cells.
Furthermore, the Wellcome, Blood Cancer UK and the National Institute of Health and Care Research (NIHR) and the NIHR GOSH Biomedical Research Centre recommended for a broader research to get more detailed insight about the process.
Furthermore, read more latest news from today, Dec 15, 2022:
Technology advances – Global
Coalition for Health AI Unveils Blueprint for Ethical AI Implementation (HIT)
Migraine: High-resolution MRI may help pinpoint some causes of these headaches (MNT)
Physician updates – Global
Vitamin D No Aid for Statin-Associated Muscle Symptoms (PW)
Fibromyalgia Presents With A Straight Neck on Radiograph (PW)
See and learn more about our website by clicking on the internal links below:
- Clinical Phases of Drug Development: Dostarlimab combination facilitates promising lung cancer survival
- Healthcare technology news: AI-enabled Imaging of Retina Can Specify Heart Disease Risk
- Latest radiotherapy news today: Radiotherapy with immunotherapy increases lung cancer survival-Hidoc Updates
- Pharma Global News: FDA approves first gene therapy for Hemophilia B–Hidoc Updates
- Healthcare News Today Features AI Tool Reduces Risk of COVID-19 – Hidoc Updates
- Government forms new regulation called the Uniform Code of Pharma Marketing Practices – Hidoc Updates
- A Rare Genetic Disorder Is Treated In The Womb – Hidoc Updates
- Simple ways to engage Doctors at Conferences? – Hidoc Updates
About Hidoc Dr:
Our company Hidoc Dr. is a Digital Platform for Doctors with an audited reach of 8 Lakh Doctors across India. Additionally, Hidoc Dr. provides Digital Marketing services to your brands to reach Doctors across all Specializations and Geographies. Furthermore, Hidoc Digital Solutions guarantee 3x Brand Recall compared to any other digital solutions today.
Leave a Reply